SCHEMBL21329628

SCHEMBL21329628

CO[C@@]1(c2cncc(I)n2)CCOC1

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 15/20 0.34
▸ ALOX5 P09917 2/20 0.34
▸ JAK1 P23458 1/20 0.34
▸ JAK2 O60674 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21330188 1.00 TYK2 (0.34) TYK2ALOX5JAK1JAK2
SCHEMBL21329630 1.00 TYK2 (0.34) TYK2ALOX5JAK1JAK2
SCHEMBL31691946 0.85 TYK2 (0.34) TYK2ALOX5JAK1JAK2
SCHEMBL21348808 0.84 ALOX5 (0.37) TYK2ALOX5JAK1JAK2
SCHEMBL21359003 0.76 TYK2 (0.35) TYK2ALOX5JAK1JAK2
SCHEMBL21329954 0.74 CYP11B2 (0.32) —
SCHEMBL21330226 0.71 ALOX5 (0.44) TYK2ALOX5JAK1JAK2
SCHEMBL21329679 0.71 ALOX5 (0.44) TYK2ALOX5JAK1JAK2
SCHEMBL21329681 0.71 ALOX5 (0.44) TYK2ALOX5JAK1JAK2
SCHEMBL21330284 0.70 TYK2 (0.45) TYK2ALOX5JAK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200255423-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC (US) 2020-08-13 — — US disclosed
US-20200255423-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC (US) 2020-08-13 — — US disclosed
WO-2019178079-A9 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC. (US) 2019-12-12 — — WO disclosed
WO-2019178079-A9 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC. (US) 2019-12-12 — — WO disclosed
WO-2019178079-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC. (US) 2019-09-19 — — WO disclosed
WO-2019178079-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC. (US) 2019-09-19 — — WO disclosed
EP-3539966-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING AbbVie Inc. (US) 2019-09-18 — — EP disclosed
EP-3539966-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING AbbVie Inc. (US) 2019-09-18 — — EP disclosed
US-20190276450-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC. 2019-09-12 — — US disclosed
US-20190276450-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING ABBVIE INC. 2019-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276450-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING PTK2B, ABL1, BTK TYK2 36/4885ALOX5 4798/4885JAK1 41/4885
US-20200255423-A1 INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING PTK2B, ABL1, BTK TYK2 36/4885ALOX5 4798/4885JAK1 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback